SRTA on Nasdaq
Strata Critical Medical, Inc.
American health services company, incorporated in Delaware. Summary from the record
Price unavailable
Last updated Oct 19, 2026.
Overview
Compare with Omada Health, Inc., DocGo Inc. or GeneDx Holdings Corp., or pick any stock.
- TickerSRTA on Nasdaq1
- IndustryServices-Health Services1
- HeadquartersNew York, New York1
- Incorporated inDE2
- Business address666 Third Avenue, 25Th Floor, New York, Ny 100172
- Filer categoryAccelerated filer2
See how the biggest companies compare on our leaderboards
Strata Critical Medical, Inc.(f/k/a Blade Air Mobility, Inc.) (“Strata” or the “Company”) is a time-critical logistics and medical services provider to the United States healthcare industry. The Company operates one of the nation’s largest air transport and surgical services networks for transplant hospitals and organ procurement organizations, offering an integrated “one call” solution for donor organ recovery. Strata’s core services include air and ground logistics, organ placement, surgical organ recovery, normothermic regional perfusion and preservation for the transplant industry, as well as perfusion staffing and equipment solutions for cardiovascular surgery centers, offered under the Trinity Medical Solutions (“Trinity”) and Keystone Perfusion Services LLC (“Keystone”) brands.3 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
20.9%Gross margin4
-11.3%Operating margin4
21.0%Net margin4
34.3%Revenue growth, 20254
14.8%Return on equity4
-$58.5MFree cash flow4
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Business segments
Logistics brought in 90% of the revenue Strata Critical Medical, Inc. broke down this way in fiscal 2025.
Business segments by year
| Business segments | 2024 | 2025 |
|---|---|---|
| Logistics | $146.8M | $176.8M |
| Clinical | $0 | $20.3M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue60¢$156.0M
- Selling, general and admin24¢$60.9M
- Profit16¢$41.3M
Out of $197.1M in revenue.4
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.4
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Revenue | $197.1M | $146.8M |
| Cost of revenue | $156.0M | $117.2M |
| Gross Profit | $41.1M | $29.6M |
| Selling, general and administrative | $60.9M | $50.9M |
| Amortization of intangible assets | $2.6M | $1.3M |
| Total operating expenses | $63.5M | $52.1M |
| Operating loss from continuing operations | -$22.4M | -$22.5M |
| Interest income | $4.2M | $7.2M |
| Change in fair value of warrant liabilities | $4.3M | -$850.0K |
| Change in fair value of assets and other liabilities | -$1.0M | $0 |
| Realized loss from sales of short-term investments | -$5.2M | $0 |
| Total other non-operating income | $2.3M | $6.4M |
| Loss from continuing operations before income taxes | -$20.1M | -$16.2M |
| Income tax expense from continuing operations | $0 | $0 |
| Net loss from continuing operations | -$20.1M | -$16.2M |
| Net income (loss) from discontinued operations | $61.4M | -$11.1M |
| Net income (loss) | $41.3M | -$27.3M |
| Continuing operations, basic (in dollars per share) | -$0 | -$0 |
| Continuing operations , diluted (in dollars per share) | -$0 | -$0 |
| Discontinued operations, basic (in dollars per share) | $1 | -$0 |
| Discontinued operations, diluted (in dollars per share) | $1 | -$0 |
| Total basic earnings (loss) per share (in dollars per share) | $0.50 | -$0.35 |
| Total diluted earnings (loss) per share (in dollars per share) | $0.50 | -$0.35 |
| Basic (in shares) | 82.1M shares | 77.5M shares |
| Diluted (in shares) | 82.1M shares | 77.5M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $31.0M | $16.1M | |
| Restricted cash | $264.0K | $263.0K | |
| Accounts receivable, net of allowance of $1,066 and $ at December 31, 2025 and December 31, 2024, respectively | $40.0M | $19.8M | |
| Short-term investments | $30.3M | $108.8M | |
| Prepaid expenses and other current assets | $24.7M | $4.7M | |
| Current assets of discontinued operations | $0 | $11.2M | |
| Total current assets | $126.2M | $160.7M | |
| Property and equipment, net | $36.4M | $28.5M | |
| Intangible assets, net | $47.5M | $8.0M | |
| Goodwill | $88.2M | $15.5M | $13.3M |
| Operating right-of-use asset | $3.1M | $2.8M | |
| Other non-current assets | $24.0M | $118.0K | |
| Non current assets of discontinued operations | $0 | $41.0M | |
| Total assets | $325.5M | $256.7M | |
| Accounts payable and accrued expenses | $19.1M | $9.2M | |
| Operating lease liability, current | $652.0K | $682.0K | |
| Current liabilities of discontinued operations | $0 | $12.8M | |
| Total current liabilities | $19.8M | $22.7M | |
| Warrant liability | $1.5M | $5.8M | |
| Operating lease liability, long-term | $2.7M | $2.3M | |
| Deferred tax liability | $348.0K | $0 | |
| Other non-current liabilities | $22.1M | $0 | |
| Non-current liabilities of discontinued operations | $0 | $3.9M | |
| Total liabilities | $46.4M | $34.7M | |
| Preferred stock, $0.0001 par value, 2,000,000 shares authorized; no shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | $0 | $0 | |
| Common stock, $0.0001 par value; 400,000,000 authorized; 86,702,183 and 79,419,028 shares issued at December 31, 2025 and December 31, 2024, respectively | $7.0K | $7.0K | |
| Additional paid in capital | $424.6M | $407.1M | |
| Accumulated other comprehensive income | $0 | $1.8M | |
| Accumulated deficit | -$145.6M | -$186.9M | |
| Total stockholders' equity | $279.1M | $221.9M | $234.3M |
| Total liabilities and stockholders' equity | $325.5M | $256.7M | |
| Allowance for credit losses | $1.1M | $0 | |
| Preferred stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Preferred stock, shares authorized (in shares) | 2.0M shares | 2.0M shares | |
| Preferred stock, shares issued (in shares) | 0 shares | 0 shares | |
| Preferred stock, shares outstanding (in shares) | 0 shares | 0 shares | |
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Common stock, shares authorized (in shares) | 400.0M shares | 400.0M shares | |
| Common stock, shares issued (in shares) | 86.7M shares | 79.4M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $31.0M | $16.1M | |
| Restricted cash | $264.0K | $263.0K | |
| Accounts receivable, net of allowance of $1,066 and $ at December 31, 2025 and December 31, 2024, respectively | $40.0M | $19.8M | |
| Short-term investments | $30.3M | $108.8M | |
| Prepaid expenses and other current assets | $24.7M | $4.7M | |
| Current assets of discontinued operations | $0 | $11.2M | |
| Total current assets | $126.2M | $160.7M | |
| Property and equipment, net | $36.4M | $28.5M | |
| Intangible assets, net | $47.5M | $8.0M | |
| Goodwill | $88.2M | $15.5M | $13.3M |
| Operating right-of-use asset | $3.1M | $2.8M | |
| Other non-current assets | $24.0M | $118.0K | |
| Non current assets of discontinued operations | $0 | $41.0M | |
| Total assets | $325.5M | $256.7M | |
| Accounts payable and accrued expenses | $19.1M | $9.2M | |
| Operating lease liability, current | $652.0K | $682.0K | |
| Current liabilities of discontinued operations | $0 | $12.8M | |
| Total current liabilities | $19.8M | $22.7M | |
| Warrant liability | $1.5M | $5.8M | |
| Operating lease liability, long-term | $2.7M | $2.3M | |
| Deferred tax liability | $348.0K | $0 | |
| Other non-current liabilities | $22.1M | $0 | |
| Non-current liabilities of discontinued operations | $0 | $3.9M | |
| Total liabilities | $46.4M | $34.7M | |
| Preferred stock, $0.0001 par value, 2,000,000 shares authorized; no shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | $0 | $0 | |
| Common stock, $0.0001 par value; 400,000,000 authorized; 86,702,183 and 79,419,028 shares issued at December 31, 2025 and December 31, 2024, respectively | $7.0K | $7.0K | |
| Additional paid in capital | $424.6M | $407.1M | |
| Accumulated other comprehensive income | $0 | $1.8M | |
| Accumulated deficit | -$145.6M | -$186.9M | |
| Total stockholders' equity | $279.1M | $221.9M | $234.3M |
| Total liabilities and stockholders' equity | $325.5M | $256.7M | |
| Allowance for credit losses | $1.1M | $0 | |
| Preferred stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Preferred stock, shares authorized (in shares) | 2.0M shares | 2.0M shares | |
| Preferred stock, shares issued (in shares) | 0 shares | 0 shares | |
| Preferred stock, shares outstanding (in shares) | 0 shares | 0 shares | |
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Common stock, shares authorized (in shares) | 400.0M shares | 400.0M shares | |
| Common stock, shares issued (in shares) | 86.7M shares | 79.4M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.4
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net income / (loss) | $41.3M | -$27.3M |
| Gain on sale of business | -$57.0M | $0 |
| Depreciation and amortization | $8.2M | $6.0M |
| Stock-based compensation | $17.8M | $19.9M |
| Change in fair value of warrant liabilities | -$4.3M | $850.0K |
| Change in fair value of assets and other liabilities | $1.0M | $0 |
| Excess of lease liability over operating right-of-use assets | $0 | -$123.0K |
| Transaction costs paid related to sale of business | -$7.4M | $0 |
| Gain on lease modification | $0 | -$622.0K |
| Acquisition consideration allocated to seller transaction expenses | -$44.3M | $0 |
| Impairment of intangible assets | $0 | $5.8M |
| Impairment of property and equipment | $1.7M | $0 |
| Realized loss from sale of short-term investments | $5.2M | $0 |
| Realized foreign exchange gain | -$798.0K | $0 |
| Accretion of interest income on held-to-maturity securities | -$2.2M | -$4.0M |
| Deferred tax expense (benefit) | $432.0K | -$255.0K |
| Other | $471.0K | $323.0K |
| Prepaid expenses and other current assets | -$1.7M | $6.4M |
| Accounts receivable | -$12.0M | -$998.0K |
| Other non-current assets | $666.0K | -$70.0K |
| Operating right-of-use assets/lease liabilities | -$88.0K | $164.0K |
| Accounts payable and accrued expenses | $2.4M | -$8.3M |
| Deferred revenue | $1.7M | -$119.0K |
| Net cash used in operating activities | -$48.9M | -$2.5M |
| Acquisitions, net of cash acquired | -$66.5M | -$2.2M |
| Cash transfer from sale of business | -$2.8M | $0 |
| Capitalized software development costs | -$1.4M | -$2.1M |
| Purchase of property and equipment, net of proceeds from disposal | -$9.6M | -$30.9M |
| Purchase of held-to-maturity investments | -$146.3M | -$143.3M |
| Proceeds from maturities of held-to-maturity investments | $226.2M | $177.4M |
| Proceeds from sale of short-term investments | $70.2M | $0 |
| Net cash provided by / (used in) investing activities (includes discontinued operations; see Note 5) | $69.8M | -$1.0M |
| Proceeds from the exercise of common stock options | $193.0K | $168.0K |
| Taxes paid related to net share settlement of equity awards | -$9.1M | -$5.7M |
| Repurchase and retirement of common stock | $0 | -$244.0K |
| Net cash used in financing activities | -$8.9M | -$5.8M |
| Effect of foreign exchange rate changes on cash balances | -$339.0K | -$80.0K |
| Net increase (decrease) in cash and cash equivalents and restricted cash | $11.6M | -$9.4M |
| Income Taxes paid | $87.0K | $0 |
| Common stock received for sale of business | $75.4M | $0 |
| Contingent consideration and indemnity holdback receivable from sale of business in prepaids and other current assets and other non-current assets, respectively | $36.4M | $0 |
| New leases under ASC 842 entered into during the period | $1.6M | $8.4M |
| Contingent consideration in accounts payable and accrued expenses and other non-current liabilities | $9.1M | $0 |
| Common stock issued for acquisition | $8.4M | $0 |
| Purchases of property and equipment and capitalized software in accounts payable and accrued expenses | $128.0K | $375.0K |
| "Modification of existing right-of-use assets (""ROU"") and lease liability" | $0 | $12.7M |
| Derecognition of ROU assets and lease liability | $0 | -$6.4M |
| Common stock issued for settlement of earn-out previously in accounts payable and accrued expenses | $0 | $3.0M |
No quarter-by-quarter statement was filed.
Leadership
Who has led Strata Critical Medical, Inc., and when. Pick a name to see everywhere that person has worked.
Chief executive
President
Chief financial officer
20202025
- Chief executive officerMelissa M. Tomkiel Sep 12, 2025 to Dec 4, 202512
- Chief executive officerWilliam A. Heyburn Sep 12, 2025 to Dec 4, 202513
- Chief executive officerLouis R. Verdetto Dec 4, 2025 to now14
- Chief executive officerScott M. Wunsch Jun 25, 2024 to Sep 12, 202515
- Chief executive officerSeth J. Bacon Sep 14, 2023 to Jun 17, 202416
- Chief executive officerEric Affeldt Sep 12, 2019 to Sep 12, 201917
- PresidentMelissa M. Tomkiel May 17, 2021 to now18
- Chief financial officerWilliam A. Heyburn May 17, 2021 to now19
Board members and other officers (18)
- Chief Technology OfficerAnatoli Arkhipenko Apr 21, 2022 to Nov 14, 202220
- Chief Accounting OfficerAmir Cohen May 17, 2021 to now21
- Chief Technology OfficerBrandon A. Keene May 17, 2021 to Nov 21, 202222
- Chief Investment OfficerMichael Mohapp Sep 12, 2019 to Sep 12, 201923
- Board memberMelissa M. Tomkiel Sep 12, 2025 to now12
- Board memberWilliam A. Heyburn Sep 12, 2025 to now13
- Board memberAndrew Lauck Mar 31, 2023 to now24
- Board memberJohn Borthwick Apr 6, 2023 to now25
- Board memberDavid Zaslav May 17, 2021 to Sep 24, 202126
- Board memberJane C. Garvey May 17, 2021 to Aug 9, 202327
- Board memberSusan M. Lyne May 17, 2021 to now28
- Board memberReginald Love Sep 27, 2021 to now29
- Board memberBrian C. Witherow Sep 12, 2019 to Sep 12, 201930
- Board memberEdward M. Philip Sep 12, 2019 to now31
- Board memberEric Affeldt Sep 12, 2019 to now17
- Board memberMartin J. Newburger Sep 12, 2019 to Sep 12, 201932
- Board memberRafael Pastor Sep 12, 2019 to Sep 12, 201933
- General counselMelissa M. Tomkiel May 17, 2021 to now18
Former names
Timeline
- Dec 4, 2025New chief executive Louis R. Verdetto becomes CEO14
- Sep 12, 2025New chief executive Melissa M. Tomkiel becomes CEO12
- Sep 12, 2025New chief executive William A. Heyburn becomes CEO13
- Jun 25, 2024New chief executive Scott M. Wunsch becomes CEO15
- Sep 14, 2023New chief executive Seth J. Bacon becomes CEO16
- Sep 12, 2019New chief executive Eric Affeldt becomes CEO17
Filings
432 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 43 major events, 263 insider forms, 38 large holders, 68 other. The latest 20:
- Oct 15, 2026SCHEDULE 13D EDGAR
- Oct 2, 2026144 EDGAR
- Sep 25, 20264 EDGAR
- Sep 25, 20264 EDGAR
- Sep 10, 20264 EDGAR
- Sep 10, 20264 EDGAR
- Sep 10, 20264 EDGAR
- Sep 10, 20264 EDGAR
- Sep 10, 20264 EDGAR
- Aug 20, 2026SCHEDULE 13G/A EDGAR
- Aug 13, 20264 EDGAR
- Aug 4, 202610-Q EDGAR
- Aug 4, 20268-K EDGAR
- Aug 3, 20264 EDGAR
- Aug 3, 20264 EDGAR
- Aug 3, 20264 EDGAR
- Aug 3, 20264 EDGAR
- Aug 3, 20264 EDGAR
- Aug 3, 20264 EDGAR
- Aug 3, 20264 EDGAR
The 432 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
129 open-market trades by officers, directors and large owners since October 2021: 5 buys and 124 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 10, 2026 | Love ReginaldDirector | Sale | 5,091 | $5.75 | $29.3K | Form 4 |
| Jun 8, 2026 | Heyburn William A.Co-CEO and CFO | Sale | 31,671 | $5.87 | $185.9K | Form 4 |
| Jun 8, 2026 | Cohen AmirChief Accounting Officer | Sale | 4,655 | $5.87 | $27.3K | Form 4 |
| Jun 8, 2026 | Tomkiel Melissa M.Co-CEO and General Counsel | Sale | 29,730 | $5.87 | $174.5K | Form 4 |
| Jun 8, 2026 | Wunsch Scott MCEO, Logistics | Sale | 5,550 | $5.87 | $32.6K | Form 4 |
| May 22, 2026 | Cohen AmirChief Accounting Officer | Sale | 40,575 | $5.91 | $239.8K | Form 4 |
| May 21, 2026 | Cohen AmirChief Accounting Officer | Sale | 10,300 | $5.79 | $59.6K | Form 4 |
| May 11, 2026 | Cohen AmirChief Accounting Officer | Sale | 14,306 | $5.79 | $82.8K | Form 4 |
| Dec 9, 2025 | Heyburn William A.Co-CEO and CFO | Buy | 17,000 | $4.47 | $76.0K | Form 4 |
| Dec 5, 2025 | LAUCK ANDREWDirector | Buy | 5,000 | $4.37 | $21.9K | Form 4 |
| Nov 20, 2025 | Love ReginaldDirector | Sale | 11,000 | $4.37 | $48.1K | Form 4 |
| Nov 19, 2025 | Love ReginaldDirector | Sale | 11,000 | $4.31 | $47.4K | Form 4 |
| Aug 4, 2025 | Tomkiel Melissa M.Co-CEO and General Counsel | Sale | 47,995 | $4.94 | $237.1K | Form 4 |
| Aug 4, 2025 | Heyburn William A.Co-CEO and CFO | Sale | 46,918 | $4.94 | $231.8K | Form 4 |
| Jun 9, 2025 | Tomkiel Melissa M.Co-CEO and General Counsel | Sale | 100,000 | $4.08 | $408.0K | Form 4 |
| Jun 9, 2025 | Heyburn William A.Co-CEO and CFO | Sale | 100,000 | $4.07 | $407.0K | Form 4 |
| Jan 7, 2025 | Heyburn William A.Co-CEO and CFO | Sale | 900 | $5.00 | $4.5K | Form 4 |
| Jan 6, 2025 | Heyburn William A.Co-CEO and CFO | Sale | 103,670 | $5.02 | $520.4K | Form 4 |
| Dec 13, 2024 | Love ReginaldDirector | Sale | 5,091 | $4.05 | $20.6K | Form 4 |
| Dec 13, 2024 | Borthwick JohnDirector | Sale | 78,291 | $4.00 | $313.2K | Form 4 |
All 129 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- Third Point LLCSCHEDULE 13D, 3 filings Aug 11, 2025 to Oct 15, 202634
- Steele ExpCo Holdings, LLCSCHEDULE 13G/A, 3 filings Jan 24, 2022 to Aug 20, 202635
- ARK Investment Management LLCSCHEDULE 13G/A, 8 filings Nov 9, 2021 to Jul 8, 202636
- Northern Right Capital Management, L.P.SCHEDULE 13G, 1 filing Jun 17, 202637
- Velibor KrsticSCHEDULE 13D/A, 4 filings Apr 7, 2026 to May 8, 202638
- BlackRockSCHEDULE 13G, 2 filings Oct 17, 2025 to Jan 21, 202639
- Amova Asset Management Americas, Inc.SC 13G/A, 4 filings Feb 14, 2022 to Nov 8, 202440
- Sumitomo Mitsui Trust GroupSC 13G/A, 4 filings Feb 4, 2022 to Nov 5, 202441
- DigitalBridgeSC 13D, 1 filing Jul 12, 202442
- HG Vora Capital Management, LLCSC 13G/A, 2 filings Feb 14, 2023 to Jun 9, 202343
- RB LIFT LLCSC 13D/A, 2 filings Jan 19, 2023 to Mar 31, 202344
- FMR LLCSC 13G/A, 1 filing Feb 9, 202245
- Magnetar Financial LLCSC 13G/A, 1 filing Jan 7, 202246
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
13F reports cover disclosed long positions in U.S. stocks only.
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18SEC EDGARMelissa M. Tomkiel, President
- 19
- 20
- 21SEC EDGARAmir Cohen, Chief Accounting Officer
- 22
- 23
- 24SEC EDGARAndrew Lauck, Board member
- 25SEC EDGARJohn Borthwick, Board member
- 26SEC EDGARDavid Zaslav, Board member
- 27SEC EDGARJane C. Garvey, Board member
- 28SEC EDGARSusan M. Lyne, Board member
- 29SEC EDGARReginald Love, Board member
- 30SEC EDGARBrian C. Witherow, Board member
- 31SEC EDGAREdward M. Philip, Board member
- 32SEC EDGARMartin J. Newburger, Board member
- 33SEC EDGARRafael Pastor, Board member
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46